Dihydropyridine calcium channel blockers and the progression of parkinsonism

Annals of Neurology

Volumn 71, Issue 3, 2012, Pages 362-369

  Marras, Connie ^a,b   Gruneir, Andrea ^c,d   Rochon, Paula ^b,c,d   Wang, Xuesong ^d   Anderson, Geoff ^d   Brotchie, Jonathan ^e   Bell, Chaim M ^b,f   Fox, Susan ^a,b   Austin, Peter C ^d  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c WOMEN S COLLEGE HOSPITAL   (Canada)

^d INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; FELODIPINE; HYDROCHLOROTHIAZIDE; NIFEDIPINE;

AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BIBLIOGRAPHIC DATABASE; CANADA; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DISEASE COURSE; DRUG EFFECT; DRUG EXPOSURE; DRUG PENETRATION; FEMALE; HAZARD RATIO; HEALTH CARE; HEALTH CARE MANAGEMENT; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NURSING HOME; PARKINSONISM; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; CALCIUM CHANNEL BLOCKERS; COHORT STUDIES; DIHYDROPYRIDINES; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERTENSION; MALE; PARKINSONIAN DISORDERS; RETROSPECTIVE STUDIES;

EID: 84859178001     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22616     Document Type: Article

References (18)

1. Surmeier DJ,. Calcium, ageing, and neuronal vulnerability in Parkinson's disease. Lancet Neurol 2007; 6: 933-938.
2. Chan CS, Guzman JN, Ilijic E, et al. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature 2007; 447: 1081-1086.
3. Kupsch A, Gerlach M, Pupeter SC, et al. Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice. Neuroreport 1995; 6: 621-625.
4. Kupsch A, Sautter J, Schwarz J, et al. 1-Methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Res 1996; 741: 185-196.
5. Becker C, Jick SS, Meier CR,. Use of antihypertensives and the risk of Parkinson disease. Neurology 2008; 70 (16 pt 2): 1438-1444.
6. Ritz B, Rhodes SL, Qian L, et al. L-type calcium channel blockers and Parkinson disease in Denmark. Ann Neurol 2010; 67: 600-606.
7. Larkin JG, Thompson GG, Scobie G, et al. Dihydropyridine calcium antagonists in mice: blood and brain pharmacokinetics and efficacy against pentylenetetrazol seizures. Epilepsia 1992; 33: 760-769.
8. Uchida S, Yamada S, Nagai K, et al. Brain pharmacokinetics and in vivo receptor binding of 1,4-dihydropyridine calcium channel antagonists. Life Sci 1997; 61: 2083-2090.
9. Yamada S, Sugimoto N, Uchida S, et al. Pharmacokinetics of amlodipine and its occupancy of calcium antagonist receptors. J Cardiovasc Pharmacol 1994; 23: 466-472.
10. Yiu S, Knaus EE,. Synthesis, biological evaluation, calcium channel antagonist activity, and anticonvulsant activity of felodipine coupled to a dihydropyridine-pyridinium salt redox chemical delivery system. J Med Chem 1996; 39: 4576-4582.
11. Quan H, Khan N, Hemmelgarn BR, et al. Validation of a case definition to define hypertension using administrative data. Hypertension 2009; 54: 1423-1428.
12. Therneau TM, Grambsch PM,. Modeling survival data: extending the Cox model. New York, NY: Springer-Verlag, 2000.
13. Weiner JP, Abrams C,. The Johns Hopkins ACG Case-Mix System. Documentation and application manual. Baltimore, MD: Johns Hopkins University Press, 2001.
14. Rodnitzky RL,. Can calcium antagonists provide a neuroprotective effect in Parkinson's disease? Drugs 1999; 57: 845-849.
15. Ton TG, Heckbert SR, Longstreth WT Jr, et al. Calcium channel blockers and beta-blockers in relation to Parkinson's disease. Parkinsonism Relat Disord 2007; 13: 165-169.
16. Louis ED, Benito-Leon J, Bermejo-Pareja F, et al. Antihypertensive agents and risk of Parkinson's disease, essential tremor and dementia: a population-based prospective study (NEDICES). Neuroepidemiology 2009; 33: 286-292.
17. Simon KC, Gao X, Chen H, et al. Calcium channel blocker use and risk of Parkinson's disease. Mov Disord 2010; 25: 1818-1822.
18. Garcia-Ruiz JP, Jimenez-Jimenez FJ, Garcia de Yebenes J,. Calcium channel blocker-induced parkinsonism: clinical features and comparisons with Parkinson's disease. Parkinsonism Relat Disord 1998; 4: 211-214.